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Abstract. Retrovirus Moloney murine leukemia virus 
(M-MuLV) matures by budding at the cell surface. 
Central to the budding process is the myristoylated vi- 
ral core protein precursor Gag which, even in the ab- 
sence of all other viral components, is capable of associ- 
ating with the cytoplasmic leaflet of the plasma 
membrane and assembling into extracellular virus-like 
particles. In this paper we have used heterologous, 
Semliki Forest virus-driven, expression of M-MuLV 
Gag to study the mechanism by which this protein is 
targeted to the cell surface. In pulse-chase experiments, 
BFA, monensin, and 20°C block did not affect incorpo- 
ration of Gag into extracellular particles thereby indi- 
cating that the secretory pathway is not involved in tar- 
geting of Gag to the cell surface. Subcellular 
fractionation studies demonstrated that newly synthe- 
sized Gag became rapidly and efficiently associated 
with membranes which had a density similar to that of 
plasma membrane-derived vesicles. Protease-protec- 
tion studies confirmed that the Gag-containing mem- 
branes were of plasma membrane origin, since in crude 
cell homogenates, the bulk of newly synthesized Gag 
was protease-resistant as expected of a protein that 
binds to the cytoplasmic leaflet of the plasma mem- 
brane. Taken together these data indicate that targeting 
of M-MuLV Gag to the cell surface proceeds via direct 
insertion of the protein to the cytoplasmic side of the 
plasma membrane. Furthermore, since the membrane 
insertion reaction is highly efficient and specific, this 
suggests that the reaction is dependent on as-yet-uni- 
dentified cellular factors. 
T 
he last step in the assembly of enveloped viruses is 
budding of the genome-containing viral core struc- 
ture  through  a  specific  membrane  compartment. 
During this process the core is wrapped into a membrane 
that is highly enriched in virally encoded spike proteins. 
Studies on genetically altered viruses have indicated that 
viral  budding  reactions  can  proceed  by  three  different 
kinds of interactions. In the case of alphaviruses, produc- 
tion of enveloped particles is strictly dependent on coex- 
pression of the core and spike proteins (33, 54), thereby in- 
dicating that the budding reaction is driven by interactions 
between the cytoplasmic core and transmembrane spike 
proteins. The envelopment of hepadnavirus core has also 
been shown to require viral spike proteins (5), but since 
hepadnaviral spike proteins are capable of self-assembling 
into subviral lipoprotein particles (50), lateral spike-spike 
interactions alone in this case are evidently sufficient to in- 
duce an extrusion of a membrane vesicle. Also, the spike 
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proteins of flaviviruses (2,  24, 34, 63)  and coronaviruses 
(58) have been demonstrated to form subviral lipoprotein 
particles. Retroviruses represent yet a third type of viral 
budding mechanism, and in this case the viral core protein 
precursor  Gag is  capable  of self-assembling into envel- 
oped virus-like particles (9, 12, 48, 53, 62), thereby indicat- 
ing that binding of a  cytoplasmic core protein  into the 
membrane and its oligomerization into a  core structure 
provide the driving force for retrovirus budding. Recently, 
it was reported that the core components of the rhabdovi- 
rus rabies virus was capable of assembling into extracellu- 
lar enveloped particles in the absence of the viral spike 
proteins (36). 
One characteristic feature of viral budding reactions is 
their localization to specific cellular compartments. The 
prevailing view has been that the site of virus budding is 
determined by intracellular localization of viral spike pro- 
teins (reviewed in reference 46).  This view assumes that 
cytoplasmic core components are devoid of targeting sig- 
nals and are recruited into the budding compartment via 
interaction with the cytoplasmic tails of the spike proteins. 
This model most likely holds true for viruses like alphavi- 
ruses and hepadnaviruses, where the core lacks membrane 
binding activity and is dependent on spike proteins for its 
envelopment (5, 33, 54, 65).  However, the model cannot 
apply to retroviruses. Budding of retroviruses occurs at the 
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ciently  assembles  into  extracellular  particles  when  ex- 
pressed alone (9, 12, 48, 53, 62), it is evident that targeting 
of Gag to the cell surface is independent of viral spike pro- 
teins.  How  this  targeting  is  achieved  is  at  present  un- 
known. 
Most retroviral Gag precursors are myristoylated pro- 
teins and are expected to be synthesized on free ribosomes 
in the cytoplasm like other myristoylated proteins (21). In 
the case of type C retroviruses (e.g., Moloney murine leu- 
kemia virus [M-MuLV] 1) and lentiviruses (e.g., Human im- 
munodeficiency virus type 1 [HIV-1]), viral core structures 
are formed at the plasma membrane, concomitantly with 
the  budding  process,  and  therefore  Gag  precursors  of 
these viruses are presumed to be targeted to the cell sur- 
face as monomers or as homo-oligomers of smaller than 
full-sized cores (61). The NH~-terminal myristate modifi- 
cation has been demonstrated to be essential for the mem- 
brane association and budding competence of these Gag 
precursors (6, 9, 12, 47). Efficient binding of HIV-1 Gag to 
membranes has been shown to require also a cluster of ba- 
sic amino acids located at the amino-terminal part of the 
protein  (64,  66).  These  basic  amino  acids  most  likely 
strengthen the membrane association of HIV-1 Gag by in- 
teracting  with  acidic  membrane  phospholipids  (35,  66). 
Similar highly basic domains are found in the amino-ter- 
mini of Gag precursors of other retroviruses as well (66), 
and so presumably in these cases, the membrane associa- 
tion is also mediated by both hydrophobic and electrosta- 
tic interactions. However, since neither myristoylated pro- 
teins nor acidic phospholipids are restricted to the plasma 
membrane (39, 56, 57), the targeting of Gag to the cell sur- 
face poses a puzzle. One possibility is that targeting is ac- 
tually achieved by quite unspecific means; Gag precursors 
could be initially randomly inserted into all membranes, 
and then routed from the endoplasmic reticulum (ER) and 
Golgi to the plasma membrane via the secretory pathway. 
Another possibility is that the membrane insertion reac- 
tion is restricted to the plasma membrane, perhaps due to 
the interaction of Gag precursors with a  specific plasma 
membrane-associated Gag "receptor" (or receptors). Pre- 
vious studies using inhibitors of the secretory pathway to 
distinguish  between these  two possibilities  have yielded 
conflicting results: the carboxylic ionophore monensin, which 
blocks the secretory pathway at the level of Golgi (t6, 55), 
has  been  reported to  decrease the  release  of M-MuLV 
particles from infected cells (18), whereas in the case of 
HIV-1, monensin was found to have no effect on the as- 
sembly of Gag into extracellular particles (42). Further- 
more, the assembly of both HIV-1 and M-MuLV Gag pre- 
cursors into extracellular particles has been reported to be 
insensitive to brefeldin A  (BFA) (26, 43), a fungal antibi- 
otic that blocks exit of proteins from the ER (23). Due to 
these conflicting results, the pathway by which retroviral 
Gag  precursors  are  targeted  to  the  cell surface  has  re- 
mained unresolved. 
In this work we have studied intracellular targeting of 
M-MuLV Gag by using recombinant Semliki Forest virus 
1. Abbreviations  used in this paper:  HIV-1 Human immunodeficiency vi- 
rus type 1; M-MuLV, Moloney murine leukemia virus; PNS, post-nuclear 
supernatant; SFV, Semliki Forest virus; TR, transferrin receptor. 
(SFV) genomes to express high levels of M-MuLV Gag in 
cells.  This  enabled  us  to  quantitatively  assay  the  mem- 
brane insertion of a newly synthesized Gag precursor. Our 
results show that  the  M-MuLV  Gag is directly inserted 
into the plasma membrane without first becoming associ- 
ated with ER or Golgi membranes. Furthermore, the in- 
sertion  of M-MuLV  Gag  to  the  plasma  membrane  was 
found to occur rapidly after the synthesis of the protein, 
with  high  efficiency and  specificity. Since the  presumed 
membrane anchor of Gag precursors is  not expected to 
confer specifiC  insertion into the plasma membrane, our 
results suggest that the membrane insertion of Gag is de- 
pendent on as-yet-unidentified cellular components. 
Materials and Methods 
Cells and Virus 
BHK-21 cells (obtained from American Type Culture Collection, Rock- 
ville, MD) were grown in BHK-21 medium supplemented with 5% FCS, 
20  mM  Hepes  (N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid,  pH 
7.3), 10% tryptose phosphate broth, and 2 mM glutamine (all cell culture 
media were from GIBCO BRL, Gaithersburg, MD). Infectious SFV parti- 
cles expressing the Gag precursor of M-MuLV were prepared by eoelec- 
troporating equal amounts (20 Ixl) of in vitro transcribed SFV-C/Pr65gag 
(53) and helper 1 (30) RNAs into 107 BHK-21 cells as described in Suoma- 
lainen and Garoff (53).  At 20-22  h  postelectroporation,  culture media 
containing infectious virus were collected and the cell debris was removed 
by centrifugation at 800 g for 15 min at  +4°C. The clarified culture me- 
dium was used for infections without further concentration. The titer of 
the virus stock was  determined by  indirect  immunofluorescence using 
polyclonal rabbit anti-p30 antiserum (a generous gift from Dr. G. Schmidt, 
Institut for Molekulare Virologic, GSF, Munich, Germany). Infectious re- 
combinant SFV particles expressing the TRA2 mutant of human transfer- 
rin  receptor  were  prepared  similarly by  using SFV-CITRA2  (53)  and 
helper 1 RNAs, and titer of the virus stock was determined by indirect im- 
munofluorescence using a  monoclonal anti-human transferrin receptor 
antibody (ascites fluid of OKT-9, preparation was provided by Dr. T. Ebel 
at the laboratory). Wild-type SFV stocks were prepared in BHK 21 cells 
as previously described (22). 
Analysis of  Release of Gag Particles  from Cells 
BHK-21 cells grown on 35-mm-diam dishes (duplicate  plates) were  in- 
fected with recombinant SFV-C/Pr65gag particles diluted in minimum es- 
sential medium (MEM) supplemented with 0.2% bovine serum albumin, 
10 mM Hepes, and 2 mM glutamine at a multiplicity of infection of ~5-10. 
After 60 min at 37°C, the virus inoculum was removed and cells were fur- 
ther incubated at 37°C in the same medium. At 4 h postinfection, intracel- 
lular methionine was depleted by incubating cells in a  methionine-free 
MEM supplemented with 10 mM Hepes and 2 mM glutamine for 30 rain 
at 37°C. After this starvation, the medium was replaced with the same me- 
thionine-free medium containing 100 p.Ci of [35S]methionine (Amersham) 
per ml, and the cells were incubated at 37°C for 5 min or 10 min (pulse). 
After the pulse, cells were washed once with chase medium (minimum es- 
sential medium supplemented with 10 mM Hepes and 2 mM glutamine 
and containing 100-fold excess of cold methionine) and then incubated in 
the same medium for 5 min to 2 h (chase). After the chase, culture media 
were collected and clarified by centrifugation in an Eppendorf centrifuge 
(5 min at 5,000 rpm at 4°C). Gag particles were harvested from clarified 
culture media by pelleting them through a 20% sucrose cushion in a Vti75 
rotor at 35,000 rpm for 1 h  at 4°C using adaptors for Eppendorf tubes 
(Beckman Instrs., Fullerton, CA). Pelleted particles were taken up into 
SDS-sample buffer and analyzed by SDS-PAGE as described (53).  Cell 
monolayers were washed with PBS (without MgC12 and CaCI2)  and solu- 
bilized with 1% SDS containing 10 mM iodoacetamide (45). Aliquots of 
cell lysates were mixed with SDS-sample buffer and analyzed by SDS- 
PAGE. Radioactivity in protein bands was determined by using a Bas-III 
Image Plate and the Bio-lmage analyzer system Bus 2000 (Fuji Photo film 
Co.). The effect of BFA on release of Gag particles was tested by includ- 
ing  10  ixg/ml of BFA  (Boehringer Mannheim Corp.,  Indianapolis,  IN, 
BFA stock prepared in ethanol [EtOH]:H20  [1:1])  into methionine-star- 
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H20 was added to the mock-treated cells. The effect of monensin on the 
release of Gag particles was tested by including 5 I~M monensin (Sigma, 
stock prepared in EtOH) into starvation, pulse and chase media, and an 
equivalent volume of EtOH was added to the mock-treated cells. To test 
the effect of 20°C block on the release of Gag particles, starvation, pulse, 
and chase were done as above except that plates were incubated in a 20°C 
water bath and media devoid of NaHCO3 was used throughout. Control 
cells were shifted to a 37°C water bath after the pulse. 
Analysis of Transport of SFV Spike Complex to the 
Cell Surface 
BHK-21 cells grown on 35-mm-diam dishes (duplicate plates) were  in- 
fected with SFV at a multiplicity of infection of 10 as described above for 
recombinant SFV infections. At 4  h  postinfection, intracellular methio- 
nine was depleted by incubating cells in a  methionine-free MEM for 30 
min, after which cells were metabolically labeled with [35S]methionine for 
10 min and chased for 5/90/180 min as described above. After the chase, 
plates were placed on ice and proteins at the plasma membrane were la- 
beled with NHS-SS-biotin (Pierce, Rockford, IL) at 4°C as described (31). 
Biotinylated proteins were precipitated from cell lysates using streptavi- 
din-agarose (Sigma) as described  (19).  Precipitates  were  taken  up into 
SDS-sample buffer and analyzed by SDS-PAGE together with aliquots of 
total cell lysates. Radioactivity in protein bands was quantitated as de- 
scribed above. The effects of BFA and monensin treatments on the trans- 
port of the spike complex to the cell surface was analyzed as described 
above for SFV-C/Pr65gag-infected cells. The analysis of the affect of 20°C 
block was done as described for SFV-C/Pr65gag-infected cells except that 
starvation and pulse were at 37°C and cells were shifted to 20°C only for 
the chase. 
Analysis of  Kinetics and Efficiency of Membrane 
Association of  M-MuL  V Gag 
BHK-21 cells grown on 55-mm-diam dishes were infected with the recom- 
binant SFV-C/Pr65gag virus as described above, At 4 h postinfection in- 
tracellular methionine was depleted from cells by a 30-min incubation in 
methionine-free MEM, after which cells were metabolically labeled with 
[35S]methionine for 5 min and chased for 0/5/15/30 min. After the chase, 
plates were placed on ice, washed twice with ice-cold PBS after which cells 
were scraped into PBS and harvested by centrifugation in an Eppendorf 
centrifuge (5 min at 2,000 rpm at 4°C). The cell pellet was taken up into 
homogenization buffer (10 mM Tris-HCl, pH 7.4~ 0.25 M sucrose, 20 ixg/ml 
PMSF [Sigma Chem. Co., St Louis, MO]) and cells were disrupted by pull- 
ing the cell suspension through a 23-G (0.6 mm×  25 mm) needle fifteen 
times. Nuclei and debris were removed by centrifugation at 5,000 rpm for 
5 rain at 4°C to yield postnuclear supernalant (PNS) fraction. Typically 
65-70% of total Gag was recovered in the PNS fraction. 2 ml 70% (wt/wt) 
sucrose was mixed with 0.5 ml PNS fraction, placed at the bottom of an 
SW50.1  centrifuge tube (Beckman Instrs.), and overlaid with 2  ml 65% 
(wt/vol) and 0.5 ml 10% (wt/vol) sucrose. The step gradient was then cen- 
trifuged to an equilibrium at 35,000 rpm for 18 h at 4°C. Fractions (1 ml) 
were collected from the top  and  aliquots of fractions were  mixed with 
SDS-sample buffer and analyzed by SDS-PAGE. Radioactivity in protein 
bands was quantitated as described above. 
Subcellular Fractionation 
BHK-21 cells grown on 55-mm-diam dishes were infected with the recom- 
binant SFV-C/Pr65gag virus, labeled with [35S]methionine for 10 min at 
4.5 h postinfection and chased for 0/10/30/60 min after which cell homoge- 
nates were prepared as described above. For the ATP depletion experi- 
ment, cells were placed on ice after pulse and incubated for 10 min in a 
glucose-free medium containing 10 mM sodium azide, 20 mM 2-deoxy-o- 
glucose, and an excess of unlabeled methionine (3, 25). Subsequently, cells 
were incubated at 37°C in the same medium for 30 min before homogeni- 
zation. A modification of the step gradient described by Saraste et al. (49) 
was used for fractionation of the PNS. Briefly, 0.5 ml PNS was mixed with 
3 ml 65% sucrose, placed at the bottom of an SW41 centrifuge tube and 
overlaid with 1 mI 53%, 2 ml each of 40%, 35% and 30%, and 1.5 ml of 
10% sucrose (all sucrose solutions were wt/wt; Beckman Instrs.). The gra- 
dient was then centrifuged to equilibrium at 37,000 rpm for 14 h at 4°C. 
Fractions (1  ml) were collected from the top,  and aliquots of fractions 
were TCA-precipitated by adding equal volume of 20% TCA. The TCA- 
precipitated proteins were taken up into SDS-sample buffer, analyzed by 
SDS-PAGE  and  radioactivity  in protein  bands was  quantitated  as  de- 
scribed above. To determine the position of ER in the gradient, PNS frac- 
tions prepared  from SFV-C/TRA2-infected ceils  that  had  been  pulse- 
labeled for 10 min and chased for 5 min were analyzed on the gradient and 
the radioactively labeled TRA2 was used as a marker for ER. The position 
of plasma membrane in the gradient was determined by analyzing PNS 
prepared  from SFV-C/TRA2-infected cells that had been pulse-labeled 
for 20 min and chased for 3 h, and the slower migrating form of TRA2 (38, 
53) was used as a  marker for the plasma membrane. Galactosyl trans- 
ferase activity, a marker for trans-Golgi, was assayed in the gradient frac- 
tions as described in Brew et al. (4). 
Protease Protection Assay 
BHK-21 cells grown on 55-mm dishes were infected with SFV-C/Pr65gag, 
and at 4.5 h  postinfection cells were metabolically labeled with [35S]me- 
thionine (100 l.zCi/1 ml) for 10 min and chased for 2 min. Cells were ho- 
mogenized in 800 ixl homogenization buffer and 100 ixl aliquots of PNS- 
fractions were treated with 8 Ixg/ml proteinase K (Boehringer Mannheim) 
for 30 min at 0°C in the presence and absence of 1% NP-40. Digestion was 
stopped by adding PMSF to a final concentration of 0.4 mg/ml and sam- 
ples were further incubated at 0°C for 10 min after which time proteins 
were TCA-precipitated by adding 100 I~l of 20% TCA. Precipitates were 
taken up into SDS-sample buffer and analyzed by SDS-PAGE. In mock- 
treated  samples, protease  was  omitted  and  in  one  control  sample the 
PMSF was present from the beginning. 
Electron Microscopy 
For the analysis of plasma membrane vs Golgi budding, SFV-C/Pr65gag- 
infected cells were fixed at 6 h post infection with 2% glntaraldehyde in 
0.1 M  sodiumcacodylate buffer (pH 7.4) for 24 h. Cells were scraped off 
with a wooden pin and pelleted at 500 g. After washing in 0.1 M sodiumca- 
codylate buffer, cells were postfixed in 2% osmium tetroxid in 0.1 M sodi- 
umcacodylate buffer (pH 7.4) at 4°C for 2 h and dehydrated for 15 min in 
70%, 95%, and 100% ethanol at 4°C. 2% uranyl acetate was added to the 
final ethanol step. After dehydration the cells were placed in pure acetone 
for 15 min and embedded in LX-112 (Ladd, Vermont) and polymerized at 
60°C. Ultrathin sections were contrasted with uranyl acetate and lead ci- 
trate and analyzed in a Phitips 420 electron microscope at 80 kV. 
Results 
Expression of  M-MuL V Gag  from Recombinant 
SFV Genomes 
Intracellular targeting of M-MuLV Gag-precursor (Pr65  gag) 
is difficult to study using wild-type M-MuLV-infected cells 
due to the low level of expression of viral proteins in these 
cells.  Therefore a  heterologous,  SFV-driven  expression 
system was chosen for the expression of Pr65  gag (30, 51). 
We have previously described the construction of a recom- 
binant SFV genome SFV-C/Pr65gag, in which the coding 
sequence of Pr65  gag is fused to the C-gene of SFV (53). 
This SFV-C/Pr65gag-genome directs a high level of synthe- 
sis of a  C-Pr65gag-fusion protein, which  is cotranslationally 
processed  into  C  and  Pr65 gag  proteins  by  the  autopro- 
teolytic  activity of the SFV  C  protein  (1, 37). In our  previ- 
ous  study  we  also showed  that  Pr65 gag expressed  from  the 
SFV-C/Pr65gag-genome  becomes  myristoylated  and  as- 
sembles  into  extracellular  virus-like  particles  which  are 
similar  to  immature  M-MuLV  virions  (53).  A  more  de- 
tailed  analysis  of the  kinetics  and  efficiency  of release  of 
Gag  particles  from  SFV-C/Pr65gag-infected  BHK-21  cells 
is presented  in Fig. 1. At 4.5 h  postinfection  cells were  met- 
abolically  labeled  with  [35S]methionine  for  5  rain  and 
chased  for 0  min-2  h, and  the  amount  of Pr65 gag in cell ly- 
sates  and  extracellular  particles  was determined.  Aliquots 
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SFV-C/Pr65gag-infected cells. SFV-C/Pr65gag-infected cells were 
metabolically labeled with [3SS]methionine for 5 min and chased 
for 0 min-2 h, and the amount of Pr65  gag in cell lysates (lanes 1-7) 
and extracellular particles (medium; lanes 8-14) was analyzed by 
SDS-PAGE and fluorography. Aliquots of cell lysates were di- 
rectly analyzed by SDS-PAGE,  whereas  extracellular particles 
were first concentrated by pelletation through a sucrose cushion. 
Proportionally  five times more of medium samples than  lysate 
samples were loaded on the gel. Lanes I and 8, 0-min chase; lanes 
2 and 9, 5-rain chase; lanes 3 and 10, 15-min chase; lanes 4 and 11, 
30-min chase; lanes 5 and 12, 45-min chase; lanes 6 and 13, 1 h 
chase; lanes 7 and 14, 2 h chase. The lower band in the cell lysates 
(C) is the capsid protein of SFV. 
of  cell  lysates  were  directly  analyzed  by  SDS-PAGE, 
whereas extracellular particles were first concentrated by 
pelletation through a sucrose cushion. Proportionally five 
times more of medium samples were loaded on the gel. As 
can be seen in Fig. 1, lanes 8-14, labeled Pr65  gag was first 
detected  in  extracellular  particles  at  the  15-min  chase 
point,  and most of Pr65  gag was released  between  15 min 
and 45 rain of chase. Maximum release was reached after 2 h 
of chase  (data  not  shown).  Quantitations  indicated  that 
~31% of synthesized Pr65  gag was released into extracellu- 
lar particles during the 2 h chase (data not shown). Thus, it 
can be concluded that the Pr65  gag expressed from the re- 
combinant SFV-C/Pr65gag-genome is efficiently incorpo- 
rated  into  extracellular  particles,  and  therefore  this  ex- 
pression system can be used as a model to study targeting 
of newly synthesized Pr65  gag to the cell surface. 
Inhibitors of the Secretory Pathway Do Not Block the 
Incorporation of Newly Synthesized M-MuL  V Gag into 
Extracellular Particles 
BFA, monensin, and 20°C-block are well-characterized in- 
hibitors of the secretory pathway that block the forward 
vesicular  traffic  from ER,  from medial-Golgi  and  from 
TGN, respectively (15,  16, 23, 55).  As a first test towards 
determining whether the secretory pathway is involved in 
the transport of M-MuLV Gag to the cell surface, we ana- 
lyzed the effects of these three inhibitors on the release of 
newly synthesized Pr65  g~g from cells. 
Fig.  2  a  shows  the  release  of  Pr65  gag  from  SFV-C/ 
Pr65gag-infected cells  in the presence and absence of 10 
txg/ml BFA. At 4.5 h postinfection cells were metabolically 
labeled with  [35S]methionine  for 10 min and chased for 5 
min or 2 h, and the amount of Pr65  gag in cell lysates and ex- 
tracellutar particles was determined as described for Fig. 1. 
BFA was added to cells 30 min before the pulse and main- 
tained  throughout  the  pulse  and  chase.  By  comparing 
lanes 4 and 8 in Fig.  2 a, it is evident that Pr65  g~g was re- 
leased as efficiently from BFA-treated cells as from mock- 
treated cells  during the 2 h chase. This strongly suggested 
that the newly synthesized Pr65  gag is not initially inserted 
into the ER. To ensure that the concentration of BFA used 
was sufficient to block the vesicular traffic from the ER, 
parallel plates were infected with wild-type SFV, and the 
transport of the viral spike protein complex to the cell sur- 
face was analyzed in the presence and absence of 10 Ixg/ml 
BFA. The SFV spike complex is composed of two integral 
membrane  proteins,  p62  and  El,  which  form  a  hetero- 
dimeric complex in the ER (29, 59, 67).  After exit of the 
spike complex from the TGN, the p62-subunit is cleaved 
by a host protease in its external domain to yield the E2 
form found in mature virions (8).  SFV-infected cells were 
pulse-labeled for 10 min, chased for 5 min to 3 h, and after 
the  chase, externally exposed  plasma  membrane-associ- 
ated proteins were labeled by biotinylation at 4°C before 
detergent  solubilization  of  cells.  Biotinylated  proteins 
were precipitated from cell lysates by streptavidin-agarose. 
Analysis of total cell lysates and streptavidin-precipitated 
proteins is shown in Fig. 2, b and c, respectively. In the ab- 
sence of BFA, the p62 subunit of the spike complex was 
efficiently converted to the E2 form, which, in the gel sys- 
tem used, comigrates with E1 (Fig. 2 b, lanes 1-3). Starting 
from the 1.5-h chase point the spike complex could be de- 
tected at the cell surface (Fig.  2 c, lanes 1-3).  In contrast, 
in the presence of BFA processing of p62 to E2 was inhib- 
ited (Fig. 2 b, lanes 4-6), and no spike complexes were cap- 
tured  by  streptavidin-precipitation  (Fig.  2  c,  lanes  4-6). 
Therefore, it  can be concluded that the concentration of 
BFA used was sufficient to block the transport of proteins 
from the ER. 
To test the effect of monensin on the release of newly 
synthesized  Pr65gag, SFV-C/Pr65gag-infected  cells  were 
pulse-labeled and chased in the presence and absence of 
5  IzM  monensin  as  described  for  the  BFA  experiment. 
Analysis of total cell lysates and extracellular particles is 
shown in Fig. 3 A. By comparing the amount of Pr65  gag in 
particles  released  from mock-treated  (lane 4)  and  mon- 
ensin-treated (lane 8) cells after 2 h of chase, it is evident 
that  monensin had no effect on incorporation of Pr65  gag 
into  extracellular  particles.  The  monensin  concentration 
used was sufficient to inhibit vesicular traffic from medial- 
Golgi, since in monensin-treated, wild-type SFV-infected 
control cells, processing of p62 to E2 was severely compro- 
mised and only small amounts of spike proteins could be 
detected at the cell surface after 3 h of chase (Fig. 3, B and 
C, respectively). 
To analyze whether inhibition of protein transport from 
TGN blocks release of newly synthesized Pr65  g~g, SFV-C/ 
Pr65gag-infected cells were shifted to 20°C at 4 h postin- 
fection,  and  after  30  min  cells  were  pulse-labeled  and 
chased at 20°C as described for the BFA experiment. Con- 
trol cells  were shifted back to 37°C after the pulse.  Since 
the rate of protein synthesis is slower at 20°C, and conse- 
quently also the incorporation of label into Pr65  gag is less 
efficient, it was necessary to concentrate Pr65  gag from cell 
lysates  by  immunoprecipitation  before  gel  analysis.  As 
shown in Fig. 4 A, incubation at 20°C did not block incor- 
poration  of  labeled  Pr65  gag  into  extracellular  particles. 
Slightly fewer particles  were  present  at  the  extracellular 
medium after 2 h of chase at 20°C as compared to chase at 
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poration  of  Pr65gag into  extracellular  particles. (a)  SFV-C/Pr65gag- 
infected  cells were  pulse-labeled  with  [35S]methionine for  10  min  and 
chased for 5 min or 2 h in the presence or absence of 10 ixg/ml BFA. The 
amount of labeled Pr65  gag in cell lysates and extracellular particles was ana- 
lyzed by SDS-PAGE as described in the legend to Fig. 1. (b and c) Analysis 
of transport  of SFV spike protein complex to the cell surface in mock- or 
BFA-treated wild-type SFV-infected  control cells. Ceils were pulse-labeled with 
[35S]methionine for 10 min, chased for 5-180 min, and plasma membrane- 
associated proteins were modified by biotinylation at 4°C before detergent 
solubilization of cells, b shows analysis of total cell lysates and c shows analysis 
of plasma membrane-associated proteins precipitated by streptavidin-agarose. 
37°C, but this difference is most likely due to a direct effect 
of the temperature on the budding process itself,  since a 
more detailed  pulse-chase analysis indicated  that the  ki- 
netics of release of Gag particles was slower at 20°C than 
at 37°C (data not shown). The 20°C block was effective in 
blocking vesicular transport from TGN, since in the SFV- 
infected control cells,  transport of the viral spike complex 
to the cell surface was inhibited at 20°C, as evidenced by 
the inefficient processing of p62 to E2 (Fig. 4 B) and by the 
inability to detect spike proteins at the cell surface by bio- 
tinylation (Fig. 4 C). 
Taken together these BFA-, monensin- and 20°C block 
results strongly suggested that Pr65  gag that is released from 
cells does not initially associate with internal membranes, 
but instead is directly inserted into the plasma membrane. 
Analysis of Intracellular Targeting of  M-MuL  V Gag by 
SubceUular Fractionation 
To obtain more concrete evidence for direct insertion of 
M-MuLV Gag into the plasma membrane, we turned  to 
subcellular fractionations. Kinetics and efficiency of mem- 
brane association of newly synthesized Pr65  gag was first de- 
termined.  At 4.5 h postinfection SFV-C/Pr65gag-infected 
cells were metabolically labeled with [35S]methionine  for 5 
rain and chased for 0 min to 30 min. Postnuclear superna- 
tant (PNS) fractions of total cell homogenates were mixed 
with 70%  (wt/wt) sucrose, placed at the bottom of a step 
gradient consisting of 65%  (wt/vol) and 10%  (wt/vol) su- 
crose,  and  membranes were  fractionated by equilibrium 
flotation during ultracentrifugation.  Membranes  float  to 
the 65-10% sucrose interphase (fraction 1), whereas solu- 
ble proteins remain at the bottom of the tube (fractions 3-5). 
Although Pr65gag, like  other myristoylated proteins,  was 
expected to be synthesized on free ribosomes in the cyto- 
plasm (21), to our surprise we could never detect a clear 
initial  soluble pool for Pr65  gag. As can be seen in Fig. 5, al- 
ready at the 0-min chase point the majority of total Pr65  ga~ 
(~64%) was found in fraction 1, and after a 15-min chase, 
the  membrane-bound  pool  of  Pr65  gag  had  increased  to 
~80%. The lower amount of label in Pr65  gag at the 0-min 
chase point is most likely due to the fact that incorporation 
of label into proteins continues for a short while after the 
onset of chase. The Pr65  gag proteins found in fraction 1 at 
the  0-min chase  point  display characteristics  of proteins 
firmly associated with membranes. When a sample of this 
fraction was treated with EDTA (50 mM), high salt (2 M 
KC1) or high pH (100 mM Na2CO3)  and subjected to re- 
centrifugation, 70-79% of total Pr65  gag again floated up to 
the membrane fraction (84% of total Pr65  gag floated up in 
the mock-treated sample; data not shown). The gradient 
used was capable of properly separating cytosolic material 
from membranes, because the soluble SFV C protein was 
only found in the bottom fractions. Taken together these 
results indicated that the newly synthesized Pr65  gag binds 
to membranes very rapidly and very efficiently. 
To determine the identity of the membranes that harbor 
the  newly synthesized Pr65  gag,  a  modification of the  su- 
crose step  gradient  described  by Saraste  et  al.  (49)  was 
used.  The  TRA2-mutant  of  human  transferrin  receptor 
was used  as  a  marker for the  ER and the plasma mem- 
brane  (53).  This  is  a  type  II integral  membrane protein 
which is synthesized in the rough ER and then transported 
to the plasma membrane. Contrary to its wild-type coun- 
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Golgi does not block incorporation of Pr65  gag into extracellular 
particles. (A) SFV-C/Pr65gag-infected cells were  pulse-labeled 
with [35S]methionine  for 10 min and chased for 5 min or 2 h in the 
presence or absence of 5 IxM monensin. The amount of labeled 
Pr65 gag in cell lysates and extracellular particles was analyzed by 
SDS-PAGE as described in the legend to Fig. 1. (B and C) Anal- 
ysis of transport of SFV spike protein complex to the cell surface 
in  mock-  or  monensin-treated  wild-type SFV-infected control 
cells. Cells were processed and analyzed as described in the leg- 
end to Fig. 2. (B) Total cell lysates. (C) Streptavidin-precipitated 
proteins. 
terpart, TRA2 does not undergo endocytosis and recycling 
due to a  deletion in its cytoplasmic tail that has removed 
the endocytosis signal (7). The newly synthesized form of 
the  TRA2  was  used  as  a  marker  for  ER.  BHK-21  cells 
were infected with a recombinant SFV-genome expressing 
TRA2 (53), and PNS fractions were prepared from cells af- 
ter a  10-min pulse and 5-min chase. As shown in Fig. 6 A, 
the major peak of radioactively labeled TRA2 was found 
in fraction 8, at the density of 1.217 g/ml. Upon transp0ft 
to the plasma membrane, TRA2 is converted to  a  slower 
F/gum 4.  Inhibition of protein transport from TGN does not block 
incorporation of Pr65 gag into extracellular particles. (A) SFV-C/ 
Pr65gag-infected cells were  pulse-labeled with [3SS]methionine 
for 10 min at 20°C and chased either at 20°C or at 37°C for 5 min 
or 2 h. Lysate and media samples were analyzed as described in 
the legend to Fig. 1, except that Pr65  gag proteins were immuno- 
precipitated from cell lysates before gel analysis. (B and C) Anal- 
ysis of transport of SFV spike protein complex to the cell surface 
in wild-type SFV-infected control cells incubated at 20°C  or at 
37°C. Cells were pulse-labeled at 37°C for 10 min, subsequently 
chased either at 20°C or at 37°C for 5-180 min and processed as 
described  in  the  legend  to  Fig.  2.  (B)  Total  cell  lysates. (C) 
Streptavidin-precipitated  proteins. 
migrating  form  (38,  53),  and  this  form  was  used  as  a 
marker for  the  plasma membrane.  The  slower migrating 
form of TRA2 truly represents the cellsurface-associated 
fraction of the protein, because essentially all of it is acces- 
sible to  exogenously  added protease  (data  not  shown). 
To obtain enough  signal into this form, TRA2-expressing 
cells were pulsed for 20 min and chased for 3 h. As shown 
in  Fi~H6-A; the  Slower migrating TRA2  form  was  fairly 
broadly distributed along the gradient, with a  major peak 
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synthesized Pr65 gag. SFV-C/Pr65gag-infected cells were  pulse- 
labeled with [35S]methionine  for 5 min and chased for 0 min, 5 
min, 15 min, or 30 min. Postnuctear supernatant fractions of total 
cell homogenates  were  mixed with  70%  (wt/wt)  sucrose,  and 
overlaid with 65% (wt/vol) and 10% (wt/vol) sucrose layers, and 
membrane-associated proteins were separated from soluble ones 
by  equilibrium  flotation  during  ultracentrifugation.  Fractions 
were collected from the top and aliquots of fractions were ana- 
lyzed by SDS-PAGE. Membrane-associated proteins are found in 
fraction 1 and soluble cytoplasmic proteins in fractions 3-5. The 
lower band (C) is the capsid protein of SFV. 
in fractions 3-5 (between densities 1.136-1.164 g/ml). Sim- 
ilar results  were  obtained  when  PNS  fractions  prepared 
from  SFV-C/TRA2- and  SFV-C/Pr65gag-coinfected cells 
were  analyzed  (data  not  shown).  The  faster  migrating 
'ER'-form of TRA2 is still identifiable in fraction 8, being 
the lower of the two bands. The broad distribution of the 
slower  migrating  TRA2  on  the  gradient  was  not  unex- 
pected, because it is a known property of the plasma mem- 
brane to break into vesicles of varying density during ho- 
mogenization  (e.g.,  49).  When  the  activity of  galactosyl 
transferase, a  marker for the trans-Golgi, was analyzed in 
the  gradient  fractions,  the  major  peak  of  activity  was 
found  in  fraction  3,  at  the  density  1.136  g/ml  (data  not 
shown). 
To determine what membranes Pr65 gag is inserted into, 
SFV-C/Pr65gag-infected  cells  were  pulse-labeled for  10 
min and chased for 0 min to i  h. As shown in Fig. 6 B, im- 
mediately after the  pulse the  majority of labeled Pr65  gag 
was  found  in  fractions  3-5.  This  distribution overlapped 
the  distribution  of  the  plasma  membrane  marker,  and 
most importantly, the peak of Pr65  gag was clearly resolved 
from the ER marker, and also separated from the peak of 
galactosyl transferase activity (see above). Thus, these re- 
sults are consistent with direct insertion of Pr65 gag into the 
plasma membrane. After 30 min of chase a slight change in 
the  distribution Pr65 gag was  evident;  labeled Pr65 gag had 
disappeared from  fraction  3  and  the  majority of Pr65 gag 
was now found in fractions 4-6, between densities 1.156- 
1.178 g/ml. This change however was not due to vesicular 
transport of Pr65 gag from one membrane organelle to an- 
other, because a  similar change was also observed under 
Figure 6.  Distribution of Pr65  gag in subcellular fractions of SFV- 
C/Pr65gag-infected  cells.  (A)  Gradient  profiles of  the  TRA2- 
mutant of human transferrin receptor used as a marker for the 
ER and the plasma membrane. Postnuclear supernatants of SFV- 
C/TRA2-infected cell homogenates prepared after a 10-min pulse 
and a 5-min chase (ER-marker) or after a 20-min pulse and 3 h 
chase (plasma membrane marker) were mixed with 65% (wt/wt) su- 
crose and overlaid with 53%, 40%, 35%, 30%, and 10% (all wt/wt) 
sucrose layers, and membranes were fractionated by equilibrium 
flotation during ultracentrifugation. Fractions were collected from 
the top and aliquots of fractions were analyzed by SDS-PAGE. 
The band marked C is the capsid protein of SFV. (B) Analyses of 
postnuclear  supernatant  fractions  of  SFV-C/Pr65gag-infected 
cells on similar gradients. Cells were pulse-labeled for 10 min and 
chased for 0 min to 1 h. Shown is only the part of the gel that con- 
tained labeled Pr65gag-band. Last panel (marked-ATP) is from a 
separate experiment and shows distribution of Pr65 gag after 30 
min of chase under conditions of ATP depletion. 
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tions when all vesicular transport is inhibited (40). Under 
ATP depletion, however, no labeled Pr65  g~g was released 
into the culture medium, thereby indicating that budding 
(or completion of the budding reaction) was inhibited un- 
der  these  conditions  (data  not  shown).  The  time-depen- 
dent  disappearance  of  labeled  Pr65  gag  from  fraction  3 
could  represent  incorporation  of  Pr65  gag  into  budding 
structures, since when extracellular Gag particles are ana- 
lyzed on similar gradients and they band in fractions 4 and 
5 (data not shown). Furthermore, when gradient fractions 
were analyzed by electron microscopy, budding structures 
were  clearly  identifiable  in  fractions  4  and  5  (data  not 
shown). With longer chase times there was also a clear de- 
crease in  the  overall intensity of Pr65  gag bands.  This de- 
crease correlated with release of labeled Pr65g ag into cul- 
ture media (data not shown). 
The  above  described  membrane  fractionatiou  studies 
not only indicated that the newly synthesized Pr65  gag is di- 
rectly inserted  into  the  plasma membrane, but they also 
suggested  that  the  membrane insertion  reaction is  strik- 
ingly specific.  However, since  medial- and cis-Golgi ele- 
ments also band  at densities  1.13-1.15  g/ml (27, 49),  the 
gradient analyses could not completely exclude the possi- 
bility that some Pr65  gag in fractions 3-5 represented pro- 
teins targeted to these Golgi elements. This possibility ap- 
pears  unlikely  in  view of the  monensin  and  20°C  block 
experiments described above. However, to firmly establish 
that  the  bulk  of Pr65  gag is  specifically  inserted  into  the 
plasma membrane, we further investigated the subcellular 
localization of the protein by protease protection analysis 
and by electron microscopy. 
Newly Synthesized Pr65  gag Is Protease-protected  in 
Cell Homogenates 
Homogenization of the plasma membrane predominantly 
yields vesicles with "right-side out"-orientation (e.g., 10), 
and therefore Pr65  gag bound to the cytoplasmic leaflet of 
the plasma membrane is expected to be protease-resistant 
unless  the  membrane is dissolved by detergents.  On  the 
other hand, Pr65  gag inserted into the cytoplasmic leaflet of 
the Golgi is expected to be protease sensitive, unless bud- 
ding into  this  compartment has  occurred.  To investigate 
the protease-sensitivity of newly synthesized Pr65  ~ag in cell 
homogenates,  we  pulse-labeled  SFV-C/Pr65gag-infected 
cells for 10 min and chased for 2 min before homogeniza- 
tion  and protease treatment.  As shown in Fig. 7, Pr65  gag 
was  protected  from exogenously  added  proteinase  K  in 
the absence of detergent, whereas in the presence of 1% 
NP-40 the protein became protease-sensitive. To rule out 
the  possibility,  however unlikely,  that  some  of the  pro- 
tease  resistance  of Pr65 gag was due  to rapid  intracellular 
budding,  the  Golgi  and  plasma  membrane  of  SFV-C/ 
Pr65gag-infected cells were examined for the presence of 
budding  profiles by electron microscopy. Sections of the 
plasma membrane and  Golgi of a  typical-infected cell is 
shown in Fig. 8 A and Fig. 8 B, respectively. M-MuLV-like 
budding profiles were abundant at the cell surface. These 
were at different stages of maturation and showed a typi- 
cal  double-layered  surface  morphology.  In  contrast,  no 
Golgi-associated budding profiles or particles could be de- 
Figure 7.  Newly synthesized  Pr65  gag is protease-resistant in cell 
homogenates. SFV-C/Pr65gag-infected  cells were pulse-labeled 
with [3SS]methionine for 10 rain and chased for 2 min. Aliquots of 
PNS fractions of crude cell homogenates were treated with pro- 
teinase K (marked protease) in the presence and absence of pro- 
tease-inhibitor phenylmethylsulfonyl  fluoride (marked inhibitor), 
or in the presence and absence of 1% NP-40 (NP-40). The lower 
band (C) is the capsid protein of SFV. Asterisk (*) indicates  a 
proteolytic product of Pr65  gag. 
tected. Furthermore, when subcellular distribution of Pr65  gag 
was analyzed by immunoelectron microscopy using a poly- 
clonal  anti-p30  antiserum  directed  against  the  capsid- 
domain of Pr65  gag and detected with protein A  conjugated 
with 10 nm gold, concentration of gold particles was found 
to be fourfold higher at the plasma membrane than in the 
cell interior (data not shown). Thus, taken together, these 
results confirmed that the bulk of Pr65  gag is specifically in- 
serted into the plasma membrane. 
Discussion 
The core protein precursor Gag is the  principle  actor in 
retroviral budding reactions at the cell surface (9, 12, 48, 
53, 62). After their synthesis most retroviral Gag proteins 
become anchored into the cytoplasmic leaflet of the plasma 
membrane via a dual motif consisting of an amino-termi- 
nal myristic acid and a  cluster of basic amino acids (6, 9, 
12, 47,  64, 66).  In this work we have studied the mecha- 
nism by which these myristoylated Gag precursors are tar- 
geted to the plasma membrane using M-MuLV Gag as an 
example. Our results indicate  that the newly synthesized 
M-MuLV Gag is directly inserted  into  the  plasma mem- 
brane, and that the membrane insertion reaction is highly 
efficient and highly specific. These conclusions are based 
on three lines of evidence. First, the well characterized in- 
hibitors  of the  secretory pathway,  BFA,  monensin,  and 
20°C  block,  did  not  inhibit  the  incorporation  of newly 
synthesized  Gag  precursors  into  extracellular  particles, 
thereby ruling out the involvement of the secretory path- 
way in  the  transport of Gag to the  cell surface.  Second, 
subcellular fractionation studies demonstrated that imme- 
diately  after  synthesis,  essentially  all  Gag  was  found  in 
light  membranes  that  had  densities  similar  to  those  of 
plasma membrane-derived vesicles. Third,  protease-pro- 
tection studies on crude cell homogenates confirmed that 
these  Gag-containing membranes indeed were of plasma 
membrane  origin,  since  the  newly  synthesized  Gag was 
found to be sequestered inside membrane vesicles, as ex- 
pected of a protein that binds to the cytoplasmic leaflet of 
the plasma membrane. The other explanation for the ob- 
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Pr65gag-infected cells.  (A)  A  typical 
view  of  the  plasma  membrane  of  a 
SFV-C/Pr65gag-infected  cell.  (B)  A 
section of the cytoplasm of the  same 
cell showing Golgi membranes; in con- 
trast to the plasma membrane, the Golgi 
membranes  are  devoid  of  M-MuLV 
budding profiles or particles. A charac- 
teristic  type  I  cytopathic  vacuole  of 
SFV-infected cells can be seen on the 
left hand side of the figure (indicated 
by an arrow). This type I  cytoplasmic 
vacuole is the site of viral RNA replica- 
tion in SFV-infected cells. Bars, 200 nm. 
served protease resistance of newly synthesized Gag, namely 
rapid intracellular budding, was ruled out by EM analysis 
of Gag-expressing cells; in these analyses budding profiles 
or  budded  particles  were  observed  only  at  the  plasma 
membrane,  not in the ER  or Golgi. Although the results 
were obtained by using a  heterologous expression system, 
we believe the conclusions are valid for wild-type M-MuLV- 
infected cells as well, because also in these cells the major- 
ity of Gag (~65%) is found in light membrane vesicles after 
a 20-min pulse and a 2-min chase (the shortest pulse-label- 
Suomalainen  et al. Moloney Murine Leukemia Virus  1849 ing conditions to give quantifiable signal) and these vesicles 
band at the same density as the Gag-containing vesicles of 
the present study (Suomalainen, M., unpublished). 
There are two previous reports, which contrary to our 
results, suggested that M-MuLV Gag precursors are tar- 
geted to the plasma membrane via the secretory pathway and 
that the membrane insertion of M-MuLV Gag is not re- 
stricted to the plasma membrane. Hansen et al. (18) postu- 
lated that at least a portion of newly synthesized M-MuLV 
Gag travels to the cell surface via vesicular transport since 
they found that monensin decreases yields of extracellular 
M-MuLV  particles.  However,  the  monensin  concentra- 
tions used in that study were five times higher than in the 
present study, and over a 6 h incubation period, this con- 
centration only produced about a  threefold reduction in 
the number of extracellular particles. Considering the tox- 
icity of monensin and the longer incubation period, the de- 
crease in particle production could have resulted from ef- 
fects  other  than  a  block  in  the  secretory pathway.  In 
agreement with our results, Krishna et al. (26) recently re- 
ported that blocking the vesicular traffic from ER by BFA 
does not inhibit release of M-MuLV particles from wild- 
type M-MuLV-infected ceils. In another paper, Hansen 
et al. (17) provided evidence for intracellular budding of 
M-MuLV in 3T3 cells thereby suggesting that the M-MuLV 
Gag is not specifically inserted into the plasma membrane. 
However, the evidence was based on electron microscopic 
analysis alone, and therefore no proper conclusions could 
be drawn about the relative efficiencies with which Gag was 
targeted to the plasma membrane vs other membrane com- 
partments. In our SFV-C/Pr65gag-infected BHK-21 cells, 
we did not observe any intracellular budding of M-MuLV 
Gag by EM. One possible explanation for these different 
results  is  that  we  used  a  transient  expression  system, 
whereas Hansen et al. (17) used cell lines stably expressing 
the M-MuLV proteins. In the latter case, the observed in- 
tracellular particles could have represented particles accu- 
mulated over a longer period of time. Our subcellular frac- 
tionation  studies  strongly  suggest  that  Gag  precursors 
targeted to the intracellular membranes would represent 
only a  minor proportion of total Gag, a  proportion that 
was undetectable in our assays. However, it cannot be ex- 
cluded that the efficiency of targeting of M-MuLV Gag to 
the cell surface might vary in different cell lines. 
The observed highly efficient and specific targeting of 
M-MuLV Gag to the plasma membrane is intriguing, be- 
cause the presumed membrane anchor of Gag,  i.e., my- 
ristate plus cluster of basic amino acids, is not expected to 
confer  specific  insertion  into  the  plasma  membrane. 
Myristoylated proteins in general are found in several cel- 
lular compartments (56) and acidic phospholipids are not 
restricted  to the  plasma  membrane  either (39,  57).  The 
most simple explanation for our results is that the mem- 
brane insertion of M-MuLV Gag is dependent on an as- 
yet-unidentified cellular factor (or factors). There are at 
least two ways that these factors could operate. First, the 
putative cellular factor(s) could be a plasma membrane- 
associated Gag "receptor" protein, which increases the af- 
finity of Gag to the plasma membrane either via stoichio- 
metric protein-protein interactions or via a catalytic inter- 
action. There is a precedent in literature for the latter type 
of receptor interaction in the targeting of a myristoylated 
protein to  a  specific membrane compartment: the  small 
GTP-binding protein ARF1  (ADP-ribosylation factor 1), 
which binds to membranes in its GTP-bound form but not 
in its GDP-bound form, is targeted to Golgi by interaction 
of ARF1  with a  Golgi membrane enzyme that catalyzes 
exchange of GDP for GTP on ARF1 (11, 20). If targeting 
of M-MuLV Gag to the plasma membrane is dependent 
on an interaction with a plasma membrane-associated re- 
ceptor, our unpublished results suggest that the putative 
receptor interaction is  unlikely to be stoichiometric (i.e 
each Gag molecule engaging in receptor interaction). This 
is  based  on  the  observation that  Gag  particles released 
from SFV-C/Pr65gag-infected cells do not contain any cel- 
lular proteins in near molar ratios to Gag (Wallengren, K., 
and H. Garoff, unpublished results). However, it is possible 
that the specific insertion of M-MuLV Gag into the plasma 
membrane is directed by two different kinds of protein- 
protein  interactions.  Since  Gag  precursors  have  a  high 
propensity for self-oligomerization, it is possible that ini- 
tially only a few molecules of Gag are required to interact 
with  a  plasma  membrane-associated  receptor  and  the 
subsequent recruitment of additional Gag precursors then 
proceeds via specific Gag-Gag interactions. It is also pos- 
sible that the putative receptor interaction is catalytic rather 
than stoichiometric. For example, the amino-terminal myris- 
tic acid on a newly synthesized Gag could be unavailable 
for membrane insertion and a conformational change on 
the  protein is  needed  for the  exposure of the  occluded 
myristoyl moiety. Specific targeting to the plasma  mem- 
brane could be achieved if this conformational change was 
brought about  by a  modification catalyzed by a  plasma 
membrane-associated enzyme. However at present  it  is 
unclear what this catalytic modification on M-MuLV Gag 
could be. According to the second model, Gag is synthe- 
sized at, or close to, the plasma membrane. One striking 
feature of the membrane insertion of Gag was the rapidity 
of the  reaction:  already  after  a  5-min  pulse  and  0-min 
chase, the majority of labeled Gag was membrane-bound, 
and we could not detect a clear initial soluble pool for the 
protein. This is in contrast to the membrane insertion of 
the cellular myristoytated protein src tyrosine kinase, which 
localizes to endosomes and focal adhesions at the plasma 
membrane; in this case the protein is first found in a soluble 
pool and becomes membrane associated only after 5 min 
of chase (28). The rapidity of the membrane insertion of 
M-MuLV Gag raises the possibility that the reaction oc- 
curs cotranslationally instead of posttranslationally. Note 
that contrary to other myristoylated proteins, the majority 
of mRNAs encoding the Gag precursor of another murine 
leukemia virus, the Rauscher murine leukemia virus, have 
been reported to be membrane-bound (13, 14).  Localiza- 
tion of Gag-encoding mRNAs  to close proximity of the 
plasma membrane could explain the observed rapid and 
specific insertion of M-MuLV Gag into the plasma mem- 
brane. This localization could be achieved via specific tar- 
geting and/or anchoring of Gag-encoding mRNAs  to the 
cytoskeletal elements underneath the plasma membrane. Al- 
though there are yet no examples of specific localization of 
mRNAs in nonpolarized cells, targeting of mRNAs to spe- 
cific sites in eggs,  oocytes, and  polarized somatic cells is 
emerging as an important mechanism for targeting of cyto- 
solic proteins in these cells (for reviews see references 52, 60). 
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membrane, i.e., direct insertion, is shared by Gag precur- 
sors of other retroviruses as well, since, e.g., monensin and 
BFA do not affect release of HIV-1 and Rous sarcoma vi- 
rus Gag precursors from cells  (26, 42, 43).  In the case of 
Rous  sarcoma  virus,  the  Gag precursor  is  not myristoy- 
lated, but instead carries an acetyl-group at its amino-ter- 
minus (44).  Interestingly,  contrary to the M-MuLV  Gag, 
when  the  HIV-1  Gag  is  expressed  from  a  recombinant 
SFV genome, it becomes less efficiently membrane-associ- 
ated  (Hewson,  R.,  and  H.  Garoff,  unpublished  results). 
This  suggests  that  the  membrane  insertion  reaction  of 
HIV-1  Gag might be dependent on some additional viral 
protein(s).  In  polarized  epithelial  cells  the  intracellular 
targeting of HIV-1  Gag can apparently be modulated by 
viral spike  proteins.  However,  when  Gag is coexpressed 
with  viral  spike  proteins,  the  particle  formation  shifts 
mainly to the basolateral surface, that is the same domain 
where vital spike proteins are targeted (32, 41). Therefore, 
the possibility that efficient membrane interaction of HIV-1 
Gag  requires  viral  spike  proteins  cannot be  excluded  at 
present. It is clear from our results that viral spike proteins 
are dispensable for efficient membrane insertion of M-MuLV 
Gag, but understanding the molecular basis of this mem- 
brane insertion will require in vitro reconstitution of the 
reaction. 
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